Chronic kidney disease acquired knowledge in a diabetic and hypertensive population using a translated and validated questionnaire

References

• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1–7. doi: 10.1016/S0140-6736(16)32064-5.
   PubMed Web of Science ®Google Scholar
• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294–1304. doi: 10.1001/jama.2019.14745.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3(1):17088. doi: 10.1038/nrdp.2017.88.
   PubMedGoogle Scholar
• Glanz K, Bishop DB. The role of behavioral science theory in development and implementation of public health interventions. Annu Rev Public Health. 2010;31:399–418. doi: 10.1146/annurev.publhealth.012809.103604.
   PubMed Web of Science ®Google Scholar
• Tuot DS, Velasquez A, McCulloch CE, et al. The kidney awareness registry and education (KARE) study: protocol of a randomized controlled trial to enhance provider and patient engagement with chronic kidney disease. BMC Nephrol. 2015;16(1):1–10. doi: 10.1186/s12882-015-0168-4.
   Google Scholar
• Lopez-Vargas PA, Tong A, Howell M, et al. Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease: a mixed-methods study. Nephrology. 2017;22(5):374–381. doi: 10.1111/nep.12829.
   PubMed Web of Science ®Google Scholar
• Luyckx VA. Nephrotoxicity of alternative medicine practice. Adv Chronic Kidney Dis. 2012;19(3):129–141. doi: 10.1053/j.ackd.2012.04.005.
   PubMed Web of Science ®Google Scholar
• White SL, Polkinghorne KR, Cass A, et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust. 2008;188(4):204–208. doi: 10.5694/j.1326-5377.2008.tb01585.x.
   PubMed Web of Science ®Google Scholar
• Valdez-Ortiz R, Navarro-Reynoso F, Olvera-Soto MG, et al. Mortality in patients with chronic renal disease without health insurance in Mexico: opportunities for a national renal health policy. Kidney Int Rep. 2018;3(5):1171–1182. doi: 10.1016/j.ekir.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, et al. [Methodological design of the national health and nutrition survey 2016]. Salud Publica Mex. 2017;59(3):299–305. doi: 10.21149/8593.
   PubMed Web of Science ®Google Scholar
• Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017;23(suppl 10):S163–S172.
   PubMed Web of Science ®Google Scholar
• Mendez-Duran A, Mendez-Bueno JF, Tapia-Yañez T, et al. Epidemiología de la insuficiencia renal crónica en méxico. Dial y Traspl. 2010;31(1):7–11. doi: 10.1016/S1886-2845(10)70004-7.
   Google Scholar
• Barraclough KA, Agar JWM. Green nephrology. Nat Rev Nephrol. 2020;16(5):257–268. doi: 10.1038/s41581-019-0245-1.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Lee A, Odden M, et al. Association of chronic kidney disease detected by creatinine and cystatin C with death and cardiovascular events among elderly Mexican-Americans: the sacramento area latino study on aging (SALSA) carmen. J Am Geriatr Soc. 2013;61(1):90–95. doi: 10.1111/jgs.12040.
   PubMed Web of Science ®Google Scholar
• Gheewala PA, Peterson GM, Zaidi STR, et al. Public knowledge of chronic kidney disease evaluated using a validated questionnaire: a cross-sectional study. BMC Public Health. 2018;18(1):1–12. doi: 10.1186/s12889-018-5301-4.
   Google Scholar
• Mota-Anaya E, Yumpo-Cardenas D, Alva-Bravo E, et al. Translation, cultural adaptation and validation of the kidney disease knowledge survey (KiKS) to spanish. Medwave. 2016;16(7):e6510. doi: 10.5867/medwave.2016.07.6510.
   PubMedGoogle Scholar
• IBM Corp. IBM SPSS statistics for MacOs. Version 25.0. Armonk (NY): IBM Corp.; 2021.
   Google Scholar
• Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. J Clin Med. 2015;4(5):948–964. doi: 10.3390/jcm4050948.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Derose SF, Nicholas S, et al. Burnt-Out diabetes: Impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr. 2009;19(1):33–37. doi: 10.1053/j.jrn.2008.11.012.
   PubMed Web of Science ®Google Scholar
• Molitoris BA, Sandoval RM, Yadav SPS, et al. Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications. Physiol Rev. 2022;102(4):1625–1667. doi: 10.1152/physrev.00014.2021.
   PubMed Web of Science ®Google Scholar
• Dickson LE, Wagner MC, Sandoval RM, et al. The proximal tubule and albuminuria: really!. J Am Soc Nephrol. 2014;25(3):443–453. doi: 10.1681/ASN.2013090950.
   PubMed Web of Science ®Google Scholar
• NORMA Oficial Mexicana NOM-251-SSA1-2009. Prácticas de higiene para el proceso de alimentos, bebidas o suplementos alimenticios. 2022 https://www.dof.gob.mx/normasOficiales/3980/salud/salud.htm
   Google Scholar
• Purón-González E, de la Garza-Salazar F, Maya-Quinta R, et al. Acute interstitial nephritis in a patient using herbal product. JAMMR. 2017;23(8):1–6. doi: 10.9734/JAMMR/2017/36146.
   Google Scholar
• Nanavati A, Herlitz LC. Tubulointerstitial injury and drugs of abuse. Adv Chronic Kidney Dis. 2017;24(2):80–85. doi: 10.1053/j.ackd.2016.09.008.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi: 10.1056/NEJMoa011161.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. doi: 10.1056/NEJMoa011489.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care. 2016;39(Supplement_2):S154–S164. doi: 10.2337/dcS15-3005.
   PubMedGoogle Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística y Geografía (INEGI). Encuesta Nacional de Salud y Nutrición (ENSANUT) 2018. https://www.inegi.org.mx/programas/ensanut/2018/#Documentacion
   Google Scholar
• Fernandes AS, Ramos CI, Nerbass FB, et al. Diet quality of chronic kidney disease patients and the impact of nutritional counseling. J Ren Nutr. 2018;28(6):403–410. doi: 10.1053/j.jrn.2017.10.005.
   PubMed Web of Science ®Google Scholar
• Cortés-Sanabria L, Ayala-Cortés RA, Calderón-García CE, et al. Retos y perspectivas de la enfermedad renal crónica en méxico: a propósito del día mundial del riñón. Rev Salud Jalisco. 2017;4:6–9.
   Google Scholar
• Metzger M, Abdel-Rahman EM, Boykin H, et al. A narrative review of management strategies for common symptoms in advanced CKD. Kidney Int Rep. 2021;6(4):894–904. doi: 10.1016/j.ekir.2021.01.038.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(suppl 1):S46–S59.
   PubMedGoogle Scholar
• Prevención, Diagnóstico y Tratamiento de la Enfermedad Renal Crónica. Guía de evidencias y recomendaciones: guía de práctica clínica. México, CENETEC; 2019. http://www.cenetec-difusion.com/CMGPC/GPC-IMSS-335-19/ER.pdf
   Google Scholar